A Real-World Study Comparing Effectiveness of Disease-Modifying Therapies (DMTs) for the Management of Multiple Sclerosis in Routine Clinical Practice using US Claims Data.

Trial Profile

A Real-World Study Comparing Effectiveness of Disease-Modifying Therapies (DMTs) for the Management of Multiple Sclerosis in Routine Clinical Practice using US Claims Data.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Fingolimod; Glatiramer acetate; Interferon beta; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2017 New trial record
    • 01 Jun 2017 Results published in the Neurology and Therapy Journal.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top